Company intelligence / Profile preview

Valion Biosciences

San Diego, California, United States

Ownership: Public · VBIO
Development stage: Other

Overview

Valion Biosciences is a biotechnology company focused on developing next-generation small molecule inhibitors for oncology. The company specializes in the modulation of the ubiquitin-proteasome system, with a primary focus on targeting deubiquitinating enzymes (DUBs) such as USP7. Their lead programs aim to restore p53 function and induce apoptosis in cancer cells by preventing the deubiquitination of key oncogenic substrates. Valion's research platform integrates structural biology and advanced medicinal chemistry to create highly selective therapeutic candidates for hard-to-treat cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Financials

Market cap: $9.9M
Total revenue: $0
Enterprise value: $25.2M

Beyond the preview

Go deeper on Valion Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valion Biosciences.

Explore the full profile